Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
darolutamide + goserelin + docetaxel
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
darolutamide + goserelin + docetaxel is a combination therapy being investigated for the treatment of androgen receptor (AR)-positive salivary gland carcinoma. This regimen combines darolutamide, a potent second-generation AR antagonist; goserelin, a gonadotropin-releasing hormone (GnRH) agonist used for androgen deprivation; and docetaxel, a taxane-based chemotherapy. The combination is part of a Phase 2 umbrella trial led by Peking Union Medical College (Cancer Hospital, Chinese Academy of Medical Sciences) aimed at evaluating precision therapies based on molecular biomarkers. By simultaneously blocking the AR signaling pathway at the receptor level, suppressing systemic androgen production, and delivering cytotoxic chemotherapy, the regimen seeks to improve outcomes in patients with advanced or recurrent AR-positive salivary malignancies.
- Other names
- darolutamide + goserelin + docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))SLCO1B3 (Organic anion transporting polypeptide 1B3)GnRHR (Gonadotropin-releasing hormone receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on darolutamide + goserelin + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on darolutamide + goserelin + docetaxel.